The video discusses three undervalued healthcare stocks: Eli Lilly (LLY), Novo Nordisk (NOVOB), and Pfizer (PFE). LLY is trading at a forward P/E of 27, NOVOB at 15, and PFE at 8.5. Revenue growth over the past decade has been positive for all three, with LLY and NOVOB demonstrating revenue growth due to weight loss and diabetes treatments. Operating profit margins are 48% for NOVOB and 43% for LLY with a return on invested capital around 30% .PFE's operating margin now at 28% and the returns on invested capital is 9.3%. The speaker highlights that an ability to research and develop new treatments. All the 3 stocks are a long-term opportunities.